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Background: Constitutive activation of signal transducer and activator of transcription signalling 3 (STAT3) has been linked with
survival, proliferation and angiogenesis in a wide variety of malignancies including hepatocellular carcinoma (HCC).
Methods: We evaluated the effect of lupeol on STAT3 signalling cascade and its regulated functional responses in HCC cells.
Results: Lupeol suppressed constitutive activation of STAT3 phosphorylation at tyrosine 705 residue effectively in a dose- and
time-dependent manner. The phosphorylation of Janus-activated kinases (JAKs) 1 and 2 and Src was also suppressed by lupeol.
Pervanadate treatment reversed the downregulation of phospho-STAT3 induced by lupeol, thereby indicating the involvement of
a phosphatase. Indeed, we observed that treatment with lupeol increased the protein and mRNA levels of SHP-2, and silencing
of SHP-2 abolished the inhibitory effects of lupeol on STAT3 activation. Treatment with lupeol also downregulated the expression
of diverse STAT3-regulated genes and decreased the binding of STAT3 to VEGF promoter. Moreover, the proliferation of various
HCC cells was significantly suppressed by lupeol, being associated with substantial induction of apoptosis. Depletion of SHP-2
reversed the observed antiproliferative and pro-apoptotic effects of lupeol.
Conclusions: Lupeol exhibited its potential anticancer effects in HCC through the downregulation of STAT3-induced pro-survival
signalling cascade.
Hepatocellular carcinoma (HCC) is the most common tumour that
originates in the liver, accounting for 70% to 85% of the total liver
cancer burden worldwide. It has great heterogeneity with respect to
tumour behaviour and disease of the underlying liver, and
primarily develops from chronic infections caused by hepatitis B
and hepatitis C viruses, alcoholic injury and to a lesser extent from
genetically determined disorders such as haemochromatosis (Jemal
et al, 2011; Baffy et al, 2012). Untreated HCC has an extremely
poor prognosis, with a median survival of 1–8 months and a 5-year
survival of B3% (Cormier et al, 2006). Existing treatment options
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including surgical resection and use of chemotherapy and/or
radiotherapy are commonly associated with severe side effects, and
are also limited by therapeutic resistance and disease recurrence
(Cervello et al, 2012; Subramaniam et al, 2013). Hence, identifica-
tion of novel agents that are nontoxic and efficacious is urgently
required for both prevention and treatment of HCC.
The signal transducer and activator of transcription signalling 3
(STAT3) protein belongs to the STAT family of transcription factors
that are activated in response to cytokines and growth factors (Ihle,
1996). Ligand-dependent activation of STAT regulatory cascades is
involved in the regulation of a variety of critical functions, including
cell differentiation, proliferation, apoptosis, angiogenesis, metastasis
and immune responses (Wang et al, 2011). The abnormal activation
of STAT proteins is frequently associated with unrestricted cell
growth and malignant transformation (Grivennikov and Karin,
2010). Most of the major human malignancies as well as tumour-
derived cell lines have been reported to contain constitutively
activated STAT proteins, especially STAT3 (Johnston and Grandis,
2011). The STAT3 has been classified as an oncogene because the
constitutively active STAT3 can mediate oncogenic transformation
in cultured cells and tumour formation in nude mice (Burke et al,
2001). The STAT3 and NF-kB are two major transcription factors
regulating the ability of pre-neoplastic and malignant cells to resist
tumour surveillance, and the inflammatory milieu promoted by
these proteins is one of the key properties that tumours must acquire
for transformation (Dey et al, 2008; Ghosh et al, 2012). Activation of
STAT3 provides a growth advantage to tumour cells, allowing
accumulation, and also confers resistance to conventional therapies
that rely on apoptotic machinery to eliminate tumour cells
(Rajendran et al, 2012; Subramaniam et al, 2013). Thus, pharma-
cological modulation of STAT3 protein can be considered as an
attractive strategy for cancer prevention and treatment.
One major source of pharmacological inhibitors of STAT3 are
agents derived from natural sources, as B70% of all anticancer
drugs being used in clinical therapy are isolated from natural sources
or bear a close structural relationship to compounds of natural
origin (Newman, 2008). In the present study, we have investigated
for the first time the effect of lupeol (Lup-20(29)-en-3H-ol), a
naturally occurring dietary pentacyclic triterpene found in a variety
of fruits, vegetables and medicinal plants, on STAT3 signalling
cascade in HCC cells. The quantification studies have shown that
lupeol is present in a significant quantity in olives (3mg g 1),
mangoes (1.80mg per pulp), aloe leaf (280mg per dry leaf), elm plant
(800mg per bark), Japanese pear (175mg per g twig bark) and
ginseng oil (15.2 mg per 100 g of oil) (Siddique et al, 2011). Lupeol
has exhibited strong antioxidant, anti-inflammatory, antiarthritic,
antimutagenic and antimalarial activities in several previously
reported in vitro and in vivo studies (Siddique and Saleem, 2011).
Lupeol has been shown to exert substantial antitumour effects in
multiple tumour cell lines and cancer models (Siddique and Saleem,
2011) and has been found to target Wnt/b-catenin signalling in
human melanoma cells (Tarapore et al, 2010), sensitise castration-
resistant prostate cancer cells to antihormone therapy (Siddique
et al, 2011), induce apoptosis in head and neck squamous cell
carcinoma by suppressing NF-kB activation (Lee et al, 2007), inhibit
the self-renewal ability of liver tumour-initiating cells (T-ICs)
present in both HCC cell lines and clinical samples (Lee et al, 2011b)
and induce apoptosis in human epidermoid carcinoma cells through
negative regulation of mitochondrial, Akt/PKB and NF-kB signal-
ling pathways (Prasad et al, 2009).
In the present report, we investigated whether lupeol can
mediate its anticancer effects in part through the modulation of the
STAT3 activation pathway. We observed that lupeol can indeed
negatively regulate both constitutive and inducible STAT3
activation, leading to suppression of proliferation, induction of
apoptosis and downregulation of expression of various prolifera-
tive, anti-apoptotic and angiogenic gene products in HCC cells.
MATERIALS AND METHODS
Reagents. Lupeol was obtained from Sigma-Aldrich (St Louis,
MO, USA). It was resuspended in warm alcohol and diluted in
dimethyl sulphoxide (DMSO) to make 10 mM stock solution and
stored at 4 1C. Further dilution was done in cell culture medium as
required. MTT, Tris, glycine, NaCl, SDS and BSA were purchased
from Sigma-Aldrich. Fetal bovine serum (FBS), RPMI-1640, 0.4%
Trypan blue vital stain, Lipofectamine 2000 and antibiotic–
antimycotic mixture were obtained from Invitrogen (Carlsbad,
CA, USA). Mouse monoclonal antibodies to Bcl-xL, Bcl-2,
survivin, VEGF and caspase-9 and rabbit polyclonal antibodies
to cyclin D1, MMP-9, SHP-2 (SH-PTP2), Bak, Bax, Bid, caspase-3,
PARP and IL-6Ra were obtained from Santa Cruz Biotechnology
(San Diego, CA, USA). Mouse monoclonal antibodies to STAT3
and caspase-8 and rabbit monoclonal antibodies against phospho-
STAT3 (Tyr 705), phospho-specific Src (Tyr 416), Src, phospho-
specific Janus-activated kinase 1 (JAK1; Tyr 1022/1023), JAK1,
phospho-specific JAK2 (Tyr 1007/1008), JAK2 and Bid (poly-
clonal) were purchased from Cell Signaling Technology (Beverly,
MA, USA). The siRNA for SHP-2 and scrambled control was
obtained from Santa Cruz Biotechnology. Goat anti-rabbit-horse
radish peroxidase (HRP) conjugate and goat anti-mouse HRP were
purchased from Sigma-Aldrich. LIVE/DEAD viability/cytotoxicity
kit was purchased from Molecular Probes, Invitrogen (Carlsbad,
CA, USA).
Cell lines. Human hepatocellular carcinoma (HCC) cell lines
HepG2 and C3A were obtained from American Type Culture
Collection (Manassas, VA, USA). The PLC/PRF5, HUH-7 and
Hep3B cells were kindly provided by Professor Kam Man Hui,
National Cancer Centre, Singapore. All the HCC cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 1 antibiotic–antimycotic solution with 10% FBS.
EMSA for STAT3 DNA binding. The STAT3 DNA binding was
analysed by electrophoretic mobility shift assay (EMSA) using a
32P-labelled high-affinity sis-inducible element (hSIE) probe
(50-CTTCATTTCCCGTAAATCCCTA-AAGCT-30 and 50-AGCT
TTAGGGATTTACGGGAAATGA-30) as previously described
(Bhutani et al, 2007). Briefly, nuclear extracts were prepared from
lupeol-treated cells and incubated with the labelled hSIE probe.
The DNA–protein complex formed was separated from free
oligonucleotide on 5% native polyacrylamide gels. To confirm the
specificity, competition using 30-fold excess unlabelled oligonu-
cleotides containing consensus or mutated STAT3 binding sites
were added for 20 min at room temperature, after incubation with
the radio-labelled oligonucleotides. The dried gels were visualised,
and the radioactive bands were quantitated with a Universal Hood
II (Bio-Rad Laboratories, Hercules, CA, USA). For additional
information, please refer to Supplementary Materials and Methods.
Statistical analysis. Data are expressed as the mean±s.d. In all
figures, vertical error bars denote the s.d. The significance of
differences between groups was evaluated by Student’s t-test and
one-way analysis of variance (ANOVA) test. A P-value of o0.05
was considered statistically significant.
RESULTS
Lupeol inhibits constitutive STAT3 phosphorylation in HepG2
cells. The HepG2 cells have been shown to express constitutive
STAT3 activation (Rajendran et al, 2011; Lepiller et al, 2013), and
hence we set out to determine whether lupeol could inhibit this
activation in these cells. The HepG2 cells were incubated with
different concentrations of lupeol for 6 h, and the phosphorylation of
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STAT3 was examined by western blot analysis using antibodies that
recognise STAT3 phosphorylation at tyrosine 705. As shown in
Figure 1B, lupeol inhibited the constitutive activation of STAT3 in a
dose-dependent manner, with maximum inhibition occurring at
B50mM. Lupeol had no effect on the expression of STAT3 protein
(Figure 1B, lower panel). We also determined the length of
incubation time required for the suppression of STAT3 activation
by lupeol. As shown in Figure 1C, the inhibition was time dependent,
with complete inhibition occurring at B6 h, again with no effect on
the expression of STAT3 protein (Figure 1C, lower panel).
Lupeol inhibits STAT3 DNA-binding activity in HepG2 cells.
The phosphorylation of STAT3 promotes homodimerisation, and
the STAT3 dimers translocate to the nucleus, where they bind to
specific DNA response elements in the promoter regions of
responsive target genes to regulate their transcription (Johnston
and Grandis, 2011; Subramaniam et al, 2013). Hence, we
determined whether lupeol can suppress DNA-binding activity of
STAT3. The EMSA analysis of nuclear extracts prepared from
HepG2 cells showed that lupeol caused a decrease in STAT3
DNA-binding activity in a dose- (Figure 1D) and time-dependent
manner (Figure 1E). Addition of excess unlabeled oligonucleotide
(competitor; 30-fold molar excess) caused a complete disappear-
ance of the band, whereas mutated oligonucleotide had no effect on
DNA binding (Figure 1F).
Lupeol reduces nuclear pool of STAT3 in HCC cells. As nuclear
translocation is central towards the functional activity of
transcription factors such as STAT3 (Subramaniam et al, 2013),
we determined whether lupeol can suppress nuclear translocation
of STAT3. Figure 1F clearly demonstrates that lupeol inhibited the
translocation of STAT3 to the nucleus in HepG2 cells.
Lupeol suppresses constitutive activation of c-Src. Signal
transducer and activator of transcription signalling 3 has also
been reported to be activated by soluble tyrosine kinases of the Src
kinase families (Yu et al, 1995; Subramaniam et al, 2013). Hence,
we determined the effect of lupeol on constitutive activation of Src
kinase in HepG2 cells. We found that lupeol suppressed the
constitutive phosphorylation of c-Src kinases (Figure 2A). The
levels of nonphosphorylated Src kinases remained unchanged
under the same conditions.
Lupeol suppresses constitutive activation of JAK1 and JAK2.
Because JAKs phosphorylate STAT proteins when activated by
signals from interleukins and other cytokines (Subramaniam et al,
2013), we next analysed whether lupeol can affect constitutive
activation of JAK1 in HepG2 cells. We found that lupeol
suppressed the constitutive phosphorylation of JAK1 (Figure 2B),
with maximum inhibition at 6 h. The levels of nonphosphorylated
JAK1 remained unchanged under the same conditions (Figure 2B,
bottom panel). To determine the effect of lupeol on JAK2
activation, HepG2 cells were treated for different time intervals
with lupeol and phosphorylation of JAK2 was analysed by western
blot. As shown in Figure 2C, JAK2 was constitutively active in
HepG2 cells and pretreatment with lupeol suppressed this
phosphorylation in a time-dependent manner.
Tyrosine phosphatases are involved in lupeol-induced inhibition
of STAT3 activation. Several protein tyrosine phosphatases
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Figure 1. (A) The chemical structure of lupeol. (B) Lupeol suppresses phospho-STAT3 levels in a dose-dependent manner. HepG2 cells
(2106 per ml) were treated with the indicated concentrations of lupeol for 6 h, after which whole-cell extracts were prepared and 30mg of protein
was resolved on 10% SDS–PAGE gel, electrotransferred onto nitrocellulose membranes and probed for phospho-STAT3. The same blots were
stripped and reprobed with STAT3 antibody to verify equal protein loading. (C) Lupeol suppresses phospho-STAT3 levels in a time-dependent
manner. The HepG2 cells (2 106 per ml) were treated with the 50mM lupeol for the indicated times, after which western blotting was performed as
described in (B). The same blots were stripped and reprobed with STAT3 antibody to verify equal protein loading. (D) Lupeol suppresses STAT3
DNA-binding ability in a dose-dependent manner in HepG2 cells. The HepG2 cells were treated with the indicated concentrations of lupeol for
6 h; nuclear extracts were prepared and analysed by EMSA using the radiolabelled oligonucleotide containing hSIE as described in the Materials
and Methods. (E) Lupeol suppresses STAT3 DNA-binding ability in HepG2 cells. The HepG2 cells were treated with 50mM lupeol for indicated time
points; nuclear extracts were prepared and analysed by EMSA using the radiolabelled oligonucleotide containing hSIE as described in the
Materials and Methods. (F) The EMSA competition assay demonstrating specificity of STAT3 binding. Nuclear extracts of untreated HepG2 cells
were prepared and analysed by EMSA using radiolabelled oligonucleotide containing hSIE along with 30-fold excess competitor (an unlabelled
oligonucleotide probe) and mutator (an unlabelled probe with a mutation that abrogates STAT3 DNA binding). (G) Lupeol causes inhibition of
translocation of STAT3 to the nucleus. The HepG2 cells (1105 per ml) were incubated with or without 50mM lupeol for 6 h and then analysed for
the intracellular distribution of STAT3 by immunocytochemistry. The same slides were counterstained for nuclei with 1 mg ml 1 DAPI for 5 min.
The results shown are representative of two independent experiments.
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(PTPs) have been implicated in the termination of STAT3
signalling, including SHP-2, PTP1B, PTPeC, TC45 and SHP-1
(Johnston and Grandis, 2011; Subramaniam et al, 2013). To
investigate whether lupeol-induced inhibition of STAT3 tyrosine
phosphorylation involves activation of any protein tyrosine
phosphatase (PTPase), we treated HepG2 cells with the
0
1.00 1.07 0.95 0.50 0.66
1.00 0.86 0.78 0.64 0.67
1.00 1.34 1.16 0.73 0.95
0.73 1.04 0.93 1.25 1.10





















1.15 1.05 1.66 1.11
0.66 0.90 0.49 0.92 1.00 0.63 0.85 0.54
0.20 0.05 0.05 0.73 0.84 1.00
1 2 4 6 Time (h)
0 1 2 4 6 Time (h)
0 1 2 4 6
0 0 1 5 25 50
+++++–
Time (h)
0 1 2 4 6 Time (h)























Fold change Fold change
STAT3
Lupeol Lupeol
SHP-2 siRNA SHP-2 siRNA
SHP-2
Scrambled siRNA Scrambled siRNA
Figure 2. Lupeol inhibits constitutively active STAT3 in HCC cells. (A) Lupeol suppresses phospho-Src levels in a time-dependent manner. The
HepG2 cells (2106 per ml) were treated with 50mM lupeol, after which whole-cell extracts were prepared and 30mg aliquots of those extracts
were resolved on 10% SDS–PAGE, electrotransferred onto nitrocellulose membranes and probed for phospho-src antibody. The same blots were
stripped and reprobed with Src antibody to verify equal protein loading. (B) Lupeol suppresses phospho-JAK1 levels in a time-dependent manner.
HepG2 cells (2106 per ml) were treated with 50mM lupeol for indicated time intervals, after which whole-cell extracts were prepared and 30mg
portions of those extracts were resolved on 10% SDS–PAGE, electrotransferred onto nitrocellulose membranes and probed against phospho-JAK1
antibody. The same blots were stripped and reprobed with JAK1 antibody to verify equal protein loading. (C) Lupeol suppresses phospho-JAK2
levels in a time-dependent manner. The HepG2 cells (2 106 per ml) were treated with 50mM lupeol for indicated time intervals, after which whole-
cell extracts were prepared and 30mg portions of those extracts were resolved on 10% SDS–PAGE, electrotransferred onto nitrocellulose
membranes and probed against phospho-JAK2 antibody. The same blots were stripped and reprobed with JAK2 antibody to verify equal protein
loading. (D) Pervanadate reverses the phospho-STAT3 inhibitory effect of lupeol. The HepG2 cells (2 106 per ml) were treated with the indicated
concentrations of pervanadate and 50 mM lupeol for 6 h, after which whole-cell extracts were prepared and 30mg portions of those extracts were
resolved on 10% SDS–PAGE gel, electrotransferred onto nitrocellulose membranes and probed for phospho-STAT3 and STAT3. (E) Lupeol
induces the expression of SHP-2 protein in HepG2 cells. The HepG2 cells were treated with indicated concentrations of lupeol for 6 h, after which
western blotting was performed using SHP-2, SHP-1 and b-actin antibodies. (F) Lupeol induces the expression of SHP-2 in HepG2 cells. The
HepG2 cells were treated with indicated concentrations of lupeol for 6 h, after which total RNA was extracted, and the mRNA level of SHP-2 was
analysed by RT–PCR. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. (G) Effect of SHP-2 knockdown on
lupeol-induced expression of SHP-2. The HepG2 cells were transfected with either SHP-2 siRNA or scrambled siRNA (50 nM). After 24 h, cells were
treated with 50mM lupeol for 6 h and whole-cell extracts were subjected to western blot analysis. (H) The HepG2 cells were transfected with either
SHP-2 siRNA or scrambled siRNA (50 nM). After 24 h, cells were treated with 50mM lupeol for 6 h and whole-cell extracts were subjected to western
blot analysis for phosphorylated STAT3. The results shown are representative of two independent experiments.
BRITISH JOURNAL OF CANCER Suppression of STAT3 signalling cascade by lupeol
1330 www.bjcancer.com | DOI:10.1038/bjc.2014.422
broad-acting tyrosine phosphatase inhibitor sodium pervanadate
and looked for reversal of lupeol-induced suppression of STAT3
activation (Figure 2D). These data suggest that tyrosine phospha-
tases may be involved in lupeol-induced inhibition of STAT3
activation in HCC cells.
Lupeol induces the expression of SHP-2 in HCC cells. The
SHP-2 is a SH-2 containing tyrosine phosphatase involved in the
suppression of a variety of cytokine signals, including STAT3
(Wormald and Hilton, 2004). Hence, we next examined whether
lupeol can induce the expression of SHP-2 and SHP-1 in HepG2
cells. The cells were incubated with 50 mM lupeol for different time
points ranging from 1 to 6 h, and whole-cell extracts were prepared
and examined for SHP-2 and SHP-1 protein expression by western
blot analysis. As shown in Figure 2E, lupeol significantly induced
the expression of SHP-2 protein in HepG2 cells in a time-
dependent manner, with maximum expression at 4–6 h, whereas it
had minimal effect on the expression of SHP-1 protein. The
increase in SHP-2 expression by lupeol correlated with down-
regulation of constitutive STAT3 activation in HepG2 cells
(Figure 1C). The two sets of data point to the fact that stimulation
of SHP-2 expression by lupeol mediates the downregulation of
constitutive STAT3 activation in HepG2 cells. Whether modula-
tion of SHP-2 by lupeol is also regulated at the transcriptional level
was investigated as well. For this, cells were incubated with
different concentrations of lupeol for 6 h, and then total RNA was
extracted, converted to cDNA and examined for SHP-2 gene
expression by reverse transcription–PCR (RT–PCR) analysis. As
shown in Figure 2F, lupeol induced the expression of SHP-2
mRNA, with maximum expression at 4 to 6 h of treatment.
SHP-2 siRNA downregulate the expression of SHP-2 induced by
lupeol. We determined the effect of SHP-2 siRNA on lupeol-
induced SHP-2 expression. As observed by western blot analysis,
lupeol-induced SHP-2 expression was effectively inhibited in the
cells transfected with SHP-2 siRNA while in the cells treated with
the (Figure 2G), sequence-randomised scrambled siRNA oligonu-
cleotide no substantial effect was noticed.
SHP-2 siRNA reversed the inhibition of STAT3 activation by
lupeol. We next determined whether the suppression of SHP-2
expression by siRNA abrogates the inhibitory effect of lupeol on
STAT3 activation. Western blot analysis shows that lupeol failed to
suppress STAT3 activation in the cells transfected with SHP-2
siRNA (Figure 2H). However, lupeol caused downregulation of
STAT3 activation in cells transfected with scrambled siRNA. These
results suggest the pivotal role of SHP-2 in suppression of STAT3
phosphorylation by lupeol.
Lupeol inhibits inducible STAT3, JAK1 and JAK2 phosphoryla-
tion in HCC cells. Because IL-6 induces STAT3 phosphorylation,
we next determined whether lupeol could inhibit IL-6-induced
STAT3 phosphorylation in HCC cells. In Hep3B cells incubated
with lupeol for different times, IL-6-induced STAT3, JAK1 and
JAK2 phosphorylation was suppressed by lupeol in a time-
dependent manner. Exposure of cells to lupeol for 4 h was
sufficient to substantially suppress IL-6-induced STAT3 phosphor-
ylation in Hep3B cells (Figure 3A). These results suggest that
lupeol can also downregulate inducible STAT3 activation in HCC
cells. Moreover, IL-6-induced STAT3 phosphorylation was blocked
by neutralising IL-6 receptor antibodies, thereby indicating the
specificity of STAT3 phosphorylation induced by IL-6 in Hep3B
cells (Figure 3A, last lane).
Lupeol suppresses EGF-induced STAT3-dependent reporter
gene expression in HCC cells. Our above results showed that
lupeol inhibited the phosphorylation and nuclear translocation of
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Figure 3. Lupeol downregulates IL-6-induced phospho-STAT3 in HCC
cells. (A) The Hep3B cells (2 106 per ml) were treated with 50mM lupeol
for the indicated times and then stimulated with IL-6 (10 ng ml1) for
15min. One set of Hep3B cells were preincubated for 18h in the
presence of neutralising IL-6 receptor antibody (1mg ml 1) before
stimulation with IL-6 to serve as a positive control. Whole-cell extracts
were then prepared and analysed for p-STAT3 by western blotting. The
same blots were stripped and reprobed with STAT3 antibody to verify
equal protein loading. (B) The Hep3B cells (2106 per ml) were treated
with 50mM lupeol for the indicated times and then stimulated with IL-6
(10ngml1) for 15 min. One set of Hep3B cells were preincubated for
18h in the presence of neutralising IL-6 receptor antibody (1mg ml 1)
before stimulation with IL-6 to serve as a positive control. Whole-cell
extracts were then prepared and analysed for p-JAK1 by western
blotting. The same blots were stripped and reprobed with JAK1 antibody
to verify equal protein loading. (C) The Hep3B cells (2 106 per ml) were
treated with 50mM lupeol for the indicated times and then stimulated with
IL-6 (10 ng ml 1) for 15min. One set of Hep3B cells were preincubated
for 18 h in the presence of neutralising IL-6 receptor antibody (1mg ml 1)
before stimulation with IL-6 to serve as a positive control. Whole-cell
extracts were then prepared and analysed for p-JAK2 by western
blotting. The same blots were stripped and reprobed with JAK2 antibody
to verify equal protein loading. (D) The PLC/PRF5 cells (5 105 per ml)
were transfected with STAT3-luciferase (STAT3-Luc) plasmid, incubated
for 48 h and treated with indicated doses of lupeol for 6 h and then
stimulated with EGF (100ng ml1) for 2 h. Whole-cell extracts were then
prepared and analysed for luciferase activity. The results shown are
representative of two independent experiments. *Po0.05. Abbreviation:
DN¼dominant negative.
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dependent gene transcription. When PLC/PRF5 cells transiently
transfected with the pSTAT3-Luc construct were stimulated with
EGF, STAT3-mediated luciferase gene expression was increased.
Transfection with dominant-negative STAT3 blocked this increase,
indicating specificity. When the cells were pretreated with lupeol,
EGF-induced STAT3 activity was inhibited in a dose-dependent
manner (Figure 3D).
Lupeol downregulates the expression of various antiprolifera-
tive, anti-apoptotic and angiogenic gene products in HCC
cells. The persistently activated STAT3 proteins in tumour cells
promote a permanent alteration of various oncogenic genes that
control cellular processes such as proliferation, survival, invasion,
angiogenesis and chemoresistance (Wang et al, 2011). Treatment
of HepG2 cells with lupeol was found to downregulate the
expression of the cell cycle regulator (cyclin D1), the antiapoptotic
proteins (Bcl-xL, survivin), the angiogenic gene product VEGF and
an important matrix metalloproteinase-9 (MMP-9) that is involved
in the degradation of cellular matrix, all of which have been
reported to be regulated by STAT3. Their expression decreased in a
time-dependent manner, with maximum suppression observed at
B48 h (Figure 4A). We also found that mRNA expression of
survivin and Mcl-1 was modulated by lupeol treatment in a time-
dependent manner, with maximum reduction observed at B24 h
after treatment (Figure 4B).
Exposure of HCC cells to lupeol decreases binding of STAT3 to
VEGF promoter. In order to understand the mechanism of
decrease in STAT3-regulated gene expression, we next performed
ChIP experiments. For this, lupeol- or vehicle-treated cells were
crosslinked at indicated time post lupeol treatment, and in vivo
binding of STAT3 was investigated. Treatment with lupeol resulted
in a significant decrease in STAT3 binding to VEGF promoter in a
time-dependent manner (Figure 4C). These data suggest that upon
exposure to lupeol, a decrease in expression of STAT3 target genes
is observed because of a decreased STAT3 binding to its promoter.
Lupeol inhibits the proliferation of HCC cells in a dose- and
time-dependent manner. As treatment with lupeol was found to
downregulate the expression of cyclin D1, a gene involved in cell
proliferation, we investigated whether lupeol can inhibit the
proliferation of various HCC cells using the MTT assay. Lupeol
inhibited proliferation of C3A, HepG2, PLC/PRF5 and HUH-7
cells in a dose- and time-dependent manner (Figure 5A).
Lupeol causes the accumulation of the cells in the sub-G1 phase
of the cell cycle. To further confirm that lupeol inhibits
proliferation of HCC cells through induction of apoptosis, we
analysed cell cycle distribution after PI staining. We found that
lupeol increased the accumulation of the cell population in the sub-
G1 phase after treatment for 6, 12 and 24 h in a time-dependent
manner, indicative of cellular apoptosis (Figure 5B).
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Figure 4. Lupeol suppresses expression of STAT3-regulated gene products involved in proliferation, survival and angiogenesis. (A) The HepG2
cells (2106 per ml) were treated with 50mM lupeol for indicated time intervals, after which whole-cell extracts were prepared and 30mg portions
of those extracts were resolved on 10% SDS–PAGE, membrane sliced according to molecular weight and probed against cyclin D1, Bcl-xL,
survivin, VEGF and MMP-9 antibodies. The same blots were stripped and reprobed with b-actin antibody to verify equal protein loading. The
results shown are representative of two independent experiments. (B) The HepG2 cells (3 105 per ml) were treated with 50 mM lupeol for the
indicated time intervals, after which cells were harvested after treatment and RNA samples were extracted. Then, 1mg portions of the respective
RNA extracts was used for reverse transcription to generate corresponding cDNA. Real-time PCR was performed to measure the relative quantities
of mRNA. Each RT product was targeted against Mcl-1 and survivin probes, with GAPDH as endogenous control for measurement of equal loading
of RNA samples. Results were analysed using Sequence Detection Software version 1.3 provided by Applied Biosystems. Relative gene expression
was obtained after normalisation with endogenous GAPDH and determination of the difference in threshold cycle (Ct) between treated and
untreated cells using 2-DDCt method. (C) Treatment with lupeol decreases binding of STAT3 to VEGF promoter. Chromatin immunoprecipitation
(ChIP) assay was performed in HepG2 cells to examine binding of STAT3 on VEGF promoter. Cells were treated with lupeol for indicated time and
crosslinked. The cell pellets were processed for ChIP as detailed under Supplementary Materials and Methods. Ratio of quantitative real-time PCR
signal in STAT3 immunoprecipitate relative to IgG (negative control) immunoprecipitate is plotted. Mean±s.d. of three experiments (*Po0.05).
BRITISH JOURNAL OF CANCER Suppression of STAT3 signalling cascade by lupeol
1332 www.bjcancer.com | DOI:10.1038/bjc.2014.422
Lupeol upregulates the expression of Bak and Bax and
downregulates Bcl-2. We found that lupeol-treated HepG2 cells
had an increase in the expression of the pro-apoptotic proteins
Bak and Bax, with maximum upregulation observed at 48 h
(Figure 5C). The expression of another important anti-apoptotic
protein, Bcl-2, was also substantially inhibited by lupeol in a time-
dependent manner (Figure 5C).
Lupeol modulates the expression of Bid. Whether lupeol can
modulate the expression of pro-apoptotic protein, Bid, was also
C3AHepG2 PLC/PRF5
Lupeol (M)
6 h 12 h 24 hControl
SubG1 : 4.5% SubG1 : 5.76% SubG1 : 11.47% SubG1 : 34.92% 
G1/G0  : 68.3% G1/G0  : 64.5% G1/G0 : 58.26% G1/G0 :  51.38%
S          : 9.9% S          : 11.04% S       :      7.74%S         : 10.71%















































































































































Figure 5. (A) The HepG2, PLC/PRF5, HUH-7 and C3A cells (5 103 per ml) were plated in triplicate, treated with indicated concentrations of
lupeol and then subjected to MTT assay after 24, 48 and 72 h to analyse proliferation of cells. The s.d. values between triplicates are indicated.
(B) The HepG2 cells (2 106 per ml) were treated with 50mM lupeol for the indicated times, after which the cells were washed, fixed, stained
with PI and analysed for DNA content by flow cytometry. (C) The HepG2 cells were treated with 50mM lupeol for the indicated times, whole-cell
extracts were prepared, separated on SDS–PAGE and subjected to western blotting against Bak, Bax and Bcl-2 antibodies. (D) The HepG2 cells
were treated with 50mM lupeol for the indicated times, whole-cell extracts were prepared, separated on SDS–PAGE and subjected to western
blotting against Bid and cleaved Bid antibodies. The same blots were stripped and reprobed with b-actin antibody to show equal protein loading.
(E) The HepG2 cells were treated with 50mM lupeol for the indicated times, whole-cell extracts were prepared, separated on SDS–PAGE and
subjected to western blotting against pro-caspase-8, pro-caspase-9, pro-caspase-3 and cleaved caspase-3 antibodies. The same blot was stripped
and reprobed with b-actin antibody to show equal protein loading. (F) The HepG2 cells were treated with 50mM lupeol for the indicated times, and
whole-cell extracts were prepared, separated on SDS–PAGE and subjected to western blot against PARP antibody. The same blot was stripped
and reprobed with b-actin antibody to show equal protein loading. The results shown are representative of two independent experiments.
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examined. We found that treatment with lupeol decreased the
expression of full-length Bid in a time-dependent manner in
HepG2 cells (Figure 5D). In addition, we noticed that lupeol
treatment caused an increase in the level of cleaved Bid.
Lupeol activates caspases and induces PARP cleavage in HCC
cells. Whether suppression of constitutively active STAT3 in
HepG2 cells by lupeol leads to apoptosis was also investigated. In
HepG2 cells treated with lupeol, there was a time-dependent
activation of the initiator caspases 8 and 9 (Figure 5E). The levels of
these pro-caspases were reduced upon treatment with lupeol, with
maximum effects observed at B48 h. There was an increase in the
levels of cleaved caspase-9 that correlated with the decrease in
pro-caspase-9 upon treatment with lupeol. There was also a time-
dependent activation of the effector molecule pro-caspase-3, with a
concomitant increase in cleaved form of caspase-3 in a time-
dependent manner (Figure 5E). Activation of downstream caspases
led to the cleavage of a 118-kDa poly(ADP-ribose) polymerase
(PARP) protein into an 85-kDa fragment (Figure 5F). This result
clearly suggests that lupeol induces caspase-3-dependent apoptosis
in HepG2 cells.
Transfection with SHP-2 siRNA abrogates antiproliferative/
pro-apoptotic effects of lupeol in HCC cells. The effect of
silencing of the SHP-2 gene on the antiproliferative effects of lupeol
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Figure 6. (A) Gene silencing of SHP-2 abolishes lupeol-induced suppression in tumour cell proliferation. The HepG2 cells were transfected with
SHP-2 siRNA or control siRNA for 48 h and then treated with 50mM lupeol for 24, 48 and 72 h. Mitochondrial dehydrogenase activity was measured
at 24, 48 and 72 h after lupeol treatment. Cell proliferation was analysed by measuring absorbance at 570 nm. *Po0.05. (B) Silencing of SHP-2
suppresses lupeol-induced apoptosis. The HepG2 cells were transfected with SHP-2 siRNA or control siRNA for 48 h and treated with 50mM
for 24 h. Apoptosis was measured by live/dead assay. Values represent the mean number of apoptotic cells±s.d. Magnification 100. (C) Wound-
healing assay for evaluating effect of lupeol on the migration of HepG2 cells. An IBIDI culture insert (IBIDI GmbH) consists of two reservoirs
separated by a 500mm thick wall created by a culture insert in a 35 mm Petri dish. For migration assay, an equal number of HepG2 cell (70 ml;
5105 cells per ml) were added into the two reservoirs of the same insert and incubated at 37 1C/5% CO2. After 12 h, the insert was gently
removed creating a gap of B500mm. The cells were treated with 50mM lupeol for 12 h before being exposed to 100 ng ml1 CXCL12 for 24 h.
Width of wound was measured at time 0 and 24 h of incubation with and without lupeol in the absence or presence of CXCL12. The representative
photographs showed the same area at time 0 and after 24 h of incubation. (D) Lupeol suppresses invasion of HepG2 cells. The HepG2 cells (2105
cells) were seeded in the top chamber of the Matrigel. After preincubation with or without 50 mM lupeol for 12 h, transwell chambers were then
placed into the wells of a 24-well plate, in which we had added either the basal medium only or basal medium containing 100 ng ml 1 CXCL12 in
a predetermined arrangement. After incubation for 24 h, cell invasion was analysed and columns represent mean number of invaded cells.
*Po0.05.
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scrambled siRNA before treatment with lupeol. We found that
lupeol decreased the proliferation of cells and that transfection with
SHP-2 siRNA reversed the antiproliferative effects of lupeol
(Figure 6A). These results suggest that SHP-2 plays a major role
in inhibiting tumour cell proliferation through inhibition of
STAT3 activation. As we found that lupeol-induced suppression
in STAT3 activation was mediated through the induction of
SHP-2, we investigated whether silencing of SHP-2 with siRNA
can abrogate lupeol-induced apoptosis in HepG2 cells. Apoptosis
was analysed through the examination of intracellular esterase
activity by live/dead assay. Transfection with SHP-2 siRNA
abolished lupeol-induced apoptosis (Figure 6B), and the percentage
of apoptotic cells was reduced from 32.7% to 11.4%, whereas
transfection with control siRNA had no significant effect on
apoptosis (a decrease from 32.7% to 30.4%).
Lupeol suppresses CXCL12-induced HepG2 cell migration and
invasion. Constitutively expressed STAT3 is involved in the
expression of MMP-2 and MMP-9 that play a major role in
tumour metastasis (Dechow et al, 2004; Li et al, 2006). Hence,
whether suppression of constitutively active STAT3 in HepG2 cells
by lupeol leads to inhibition in cell migration and invasion was also
investigated. Effect of lupeol on HepG2 cell migration was analysed
using an in vitro wound-healing assay. We found that HepG2 cells
migrated faster under the influence of CXCL12 and this effect was
significantly abolished on treatment with lupeol (Figure 6C). Using
an in vitro invasion assay, we also found that CXCL12 significantly
induced the invasion of HepG2 cells and that lupeol significantly
abrogated the invasive activity (Figure 6D).
DISCUSSION
The pivotal aim of this study was to determine whether lupeol
exerts its anticancer effects through the abrogation of the STAT3
signalling pathway in HCC cells. We found that this triterpene
suppressed both constitutive and inducible STAT3 activation in
human HCC cells in parallel with the inhibition of JAK1, JAK2 and
Src activation. Lupeol also downregulated the expression of
STAT3-regulated gene products, including cyclin D1, Bcl-2, Bcl-
xL, survivin, VEGF and MMP-9 proteins. It also caused the
inhibition of proliferation, increased accumulation of cells in sub-
G1 phase and significantly attenuated migratory and invasive
potential of HCC cells. Aberrant STAT3 activation has been linked
to oncogenesis in a variety of human tumours including HCC, and
our studies indicate for the first time that lupeol may also exert its
anticancer effects through the modulation of STAT3 signalling
cascade.
Whether investigated by western blot analysis for STAT3
phosphorylation at tyrosine 705 residue, by nuclear translocation
or by EMSA experiments, we noticed that lupeol substantially
suppressed STAT3 activation in HCC cells. We found that lupeol
also suppressed STAT3 activation induced by IL-6, one of the
many tumour cell growth factors that activate STAT3 (Bromberg
and Wang, 2009). The doses required to inhibit STAT3 activation
were more or less comparable to rationally designed pharmaco-
logical blockers that inhibit STAT3 dimerisation (Fuke et al, 2007).
The inhibitory effects of lupeol on STAT3 phosphorylation
correlated with the suppression of activation of upstream protein
tyrosine kinases (c-Src, JAK1 and JAK2) in a time-dependent
manner in HCC cells. Prior studies have indicated that Src and
JAK kinases activities cooperate to mediate constitutive activation
of STAT3 in tumour cells (Garcia et al, 2001). Our data also
indicate that lupeol may abrogate cooperation of Src and JAKs
involved in tyrosyl phosphorylation of STAT3 in HCC cells. The
roles of JAKs and Akt have been implicated in IL-6-induced
STAT3 activation (Ihle, 1996; Chen et al, 1999). We found that
IL-6-induced STAT3, JAK1 and JAK2 activation was also
suppressed by lupeol in HCC cells. We further noticed that lupeol
also suppressed nuclear translocation and EGF-induced reporter
activity of STAT3. This suggests that this triterpene could manifest
its effect on both constitutive and inducible STAT3 activation
through multiple mechanism(s). We postulate that STAT3
inhibitory effects of lupeol as reported here can substantially
contribute to its previously reported growth inhibitory and apoptotic
effects in HCC cells (Baffy et al, 2012). Interestingly, it has been
previously documented that lupeol can also target liver tumour-
initiating cells through phosphatase and tensin homologue modula-
tion in both HCC cell lines and clinical samples (Lee et al, 2011b).
Because CD24þ liver stem cells can also drive self-renewal and
tumour initiation through STAT3-mediated regulation of NANOG
gene (Lee et al, 2011a), it is feasible that STAT3 inhibitory effects of
lupeol may also mediate its liver stem cell-targeting effects.
The phosphorylation of STAT3 plays a key role in proliferation,
survival and angiogenesis of tumour cells (Yue and Turkson, 2009).
Diverse types of cancer, including head and neck (Li et al, 2013),
multiple myeloma (Kannaiyan et al, 2011), prostate (Shanmugam
et al, 2011), breast (Kim et al, 2013) and lymphomas and
leukaemias (Zhang et al, 2002), express constitutively active
STAT3. The suppression of constitutively active STAT3 in HCC
cells by lupeol raises the possibility that this novel STAT3 inhibitor
might also target deregulated STAT3 activation in other types of
tumour cells. Moreover, it has been reported that lupeol can also
abrogate several oncogenic signal transduction cascades including
NF-kB, PI3K/Akt and Wnt/b-catenin in tumour cells (Siddique
and Saleem, 2011). Interestingly, it has been found that STAT3 can
indeed prolong NF-kB nuclear retention through acetyltransferase
p300-mediated RelA acetylation, thereby interfering with NF-kB
nuclear export (Lee et al, 2009). Thus, it is quite feasible that the
inhibition of STAT3 activation may also mediate suppression of
NF-kB signalling by lupeol.
Under normal conditions, both the amplitude and duration of
receptor-induced STAT3 activation are tightly controlled by a
variety of endogenous protein regulators (Cervello et al, 2012;
Subramaniam et al, 2013). Numerous PTPs are involved in the
regulation of JAK/STAT signalling, including SHP1, SH-PTP2,
CD45, PTP1B, TC-PTP, PTPRT and PTP-BL (Xu and Qu, 2008).
The SHP2 is a ubiquitously expressed SH2 domain-containing
PTP. The STATs can be inactivated by SHP-2 in both the
cytoplasm and the nucleus (Shuai and Liu, 2003). We found that
pervanadate treatment could reverse the lupeol-induced down-
regulation of STAT3 in HCC cells, thereby possibly suggesting the
involvement of a tyrosine phosphatase. Indeed, we noticed that
lupeol treatment substantially increased the expression of SHP-2 at
both protein and mRNA levels that correlated with downregulation
of constitutive STAT3 phosphorylation. Transfection with SHP-2
siRNA reversed the STAT3 inhibitory effect of lupeol, thereby
further implicating a critical role of this phosphatase in lupeol-
induced abrogation of STAT3 activation. Interestingly, the multi-
kinase protein tyrosine inhibitor sorafenib approved by FDA for
the treatment of HCC has also found to act through a similar
molecular mechanism and inhibit STAT3 activation through the
induction of a phosphatase (Yang et al, 2010).
Once activated in malignant cells, STAT3 can induce the
expression of a subset of genes whose products are important.
Cancer cells harbouring aberrant STAT3 activity display elevated
levels of anti-apoptotic (Bcl-2, Bcl-xL and survivin), cell cycle
regulatory proteins (cyclin D1, c-Myc) and invasive/angiogenic
gene products (MMP-9 and VEGF) (Page et al, 2011). Moreover,
constitutively active STAT3 has been demonstrated to mediate
uncontrolled malignant cell proliferation and directly contribute to
tumourigenesis (Yue and Turkson, 2009). We analysed the effect of
lupeol on proliferation and noticed that this triterpene could
significantly suppress growth potential of four different HCC cell
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lines (HepG2, PLC/PRF5, C3A and HUH-7) in a dose- and time-
dependent manner. The downregulation of cyclin D1 expression
by lupeol directly correlated with suppression in proliferation as
observed in various HCC cell lines. Constitutive activation of
STAT3 contribute to the upregulation of Bcl-xL in ovarian cancer
cell lines that contributes to the survival advantage of human
ovarian carcinoma (Burke et al, 2001). Activation of STAT3
signalling can also induce expression of survivin gene that was
found to confer resistance to apoptosis in human breast cancer cells
(Gritsko et al, 2006). Hence, tumour cells containing persistently
activated STAT3 are more resistant to environmental apoptotic cues
and conventional chemotherapies that rely on the apoptotic pathway
for chemotherapy-induced cell death. Thus, the downregulation of
the expression of Bcl-2, Bcl-xL and survivin is likely linked with
lupeol’s ability to induce apoptosis that is evident by increase in
accumulation of lupeol-treated cells in the sub-G1 phase, processing
of the initiator caspases (caspase-8 and -9), activation of the effector
caspase-3 and cleavage of PARP in HCC cells.
Our results also show that silencing SHP-2 can abrogate the
inhibitory effect of lupeol on STAT3 activation, as well as abolish
the antiproliferative and pro-apoptotic effects of lupeol. These
findings suggest that lupeol is inhibiting tumour cell proliferation
and inducing apoptosis through upregulation of SHP-2 and
concomitant inhibition of STAT3 activation. The downmodulation
of VEGF expression is in line with a recent report in which siRNA
targeting VEGF inhibits HCC growth and tumour angiogenesis
in vivo (Raskopf et al, 2008). The suppression of MMP-9 protein
expression as observed here may contribute to the inhibitory effects
of lupeol on the migratory and invasive potential of HCC cells.
Overall, our findings indicate that lupeol interferes with several
oncogenic molecules involved in tumour initiation and progression
in HCC cells.
In conclusion, our data convincingly demonstrate that lupeol can
negatively regulate both constitutive and inducible STAT3 activation
through the suppression of upstream kinases and induction of
phosphatase SHP-2 in HCC cell lines, making it a potentially
effective suppressor of tumour cell survival and proliferation. Because
of its potential efficacy in suppression of the deregulated STAT3
activation and low toxicity profile, lupeol may emerge as a novel
candidate for HCC therapy. Additional studies in animals are
required to validate these findings under in vivo settings.
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